Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Thrombosis and Thrombolysis
Erschienen in: Journal of Thrombosis and Thrombolysis 2/2020

05.12.2019

Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders

verfasst von: Hassan Alipanahzadeh, Reza Ghulamreza, Mohammad Shokouhian, Marziye Bagheri, Mohsen Maleknia

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Deep vein thrombosis (DVT) is a common complication in hematologic malignancies and immunologic disorders that coagulation and inflammatory factors play a crucial role in its occurrence. The content used in this article has been obtained by PubMed database and Google Scholar search engine of English-language articles (1980–2019) using the “Deep vein thrombosis,” “Hematologic malignancies,” “Immunologic disorders” and “Treatment.” Increased levels of coagulation factors, the presence of genetic disorders, or the use of thrombotic drugs that stimulate coagulation processes are risk factors for the development of DVT in patients with hematologic malignancies. Inflammatory and auto-anti-inflammatory factors, along with coagulant factors, play an essential role in the formation of venous thrombosis in patients with immunological disorders by increasing the recruitment of inflammatory cells and adhesion molecules. Therefore, anti-coagulants in hematologic malignancies and immunosuppressants in immune disorders can reduce the risk of developing DVT by reducing thrombotic and inflammatory activity. Considering the increased risk of DVT due to impaired coagulation and inflammation processes, analysis of coagulation and inflammatory factors have prognostic values in patients with immunologic deficiencies and hematologic malignancies. Evaluation of these factors as diagnostic and prognostic biomarkers in the prediction of thrombotic events could be beneficial in implementing effective treatment strategies for DVT.
Literatur
1.
Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P et al (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117(1):19–25PubMed
2.
Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 9(1):1PubMedPubMedCentral
3.
Di Nisio M, van Es N, Büller HR (2016) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060–3073PubMed
4.
Kyrle PA, Eichinger S (2005) Deep vein thrombosis. Lancet 365(9465):1163–1174PubMed
5.
6.
van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95(9):2855–2859PubMed
7.
Tang J, Zhu W, Mei X, Zhang Z (2018) Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty. J Orthop Surg Res 13(1):8PubMedPubMedCentral
8.
Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M et al (2002) The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 162(20):2357–2360PubMed
9.
Tamaki H, Khasnis A (2015) Venous thromboembolism in systemic autoimmune diseases: a narrative review with emphasis on primary systemic vasculitides. Vasc Med 20(4):369–376PubMed
10.
Agirbasli M, Inanc N, Baykan O, Direskeneli H (2006) The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 24(5):580–583PubMed
11.
Elice F, Rodeghiero F (2012) Hematologic malignancies and thrombosis. Thromb Res 129(3):360–366PubMed
12.
Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL (2014) Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis 38(3):306–313PubMedPubMedCentral
13.
Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N et al (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113(8):636–642PubMed
14.
Martinelli I, Battaglioli T, Razzari C, Mannucci P (2007) Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 5(1):98–101PubMed
15.
16.
Cantu C, Alonso E, Jara A, Martínez L, Ríos C, de ML Fernandez et al (2004) Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke 35(8):1790–1794PubMed
17.
Radulescu VC, D’Orazio JA (2016) Venous thromboembolic disease in children and adolescents. In: Thrombosis and embolism: from research to clinical practice. Springer, Cham, p 149–165
18.
von Brühl M-L, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M et al (2012) Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209(4):819–835
19.
Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M et al (2011) von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood 117(4):1400–1407PubMedPubMedCentral
20.
Brill A, Yesilaltay A, De Meyer SF, Kisucka J, Fuchs TA, Kocher O et al (2012) Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. Arterioscler Thromb Vasc Biol 32(8):1841–1847PubMedPubMedCentral
21.
Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH (2005) High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 112(6):893–899PubMed
22.
23.
Hill A, Kelly RJ, Hillmen P (2013) Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 121(25):4985–4996PubMed
24.
Kristinsson SY (2010) Thrombosis in multiple myeloma. ASH Educ Program Book 2010(1):437–444
25.
Colombo R, Gallipoli P, Castelli R (2014) Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk 14(6):441–450PubMed
26.
Franchini M (2015) Thromboembolic risk in hematological malignancies. Clin Chem Lab Med 53(8):1139–1147PubMed
27.
Castelli R, Ferrari B, Cortelezzi A, Guariglia A (2010) Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 8(4):482–494PubMed
28.
Carrabba G, Riva M, Conte V, Di Cristofori A, Caroli M, Locatelli M et al (2018) Risk of post-operative venous thromboembolism in patients with meningioma. J Neurooncol 138(2):401–406PubMed
29.
Hoefnagel D, Kwee LE, van Putten EH, Kros JM, Dirven CM, Dammers R (2014) The incidence of postoperative thromboembolic complications following surgical resection of intracranial meningioma. A retrospective study of a large single center patient cohort. Clin Neurol Neurosurg 123:150–154PubMed
30.
Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist U-H, Björkholm M et al (2008) Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112(9):3582–3586PubMedPubMedCentral
31.
Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060PubMed
32.
Carr ME Jr, Dent RM, Carr SL (1996) Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 128(1):83–88PubMed
33.
Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW (2007) Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 92(2):279–280PubMed
34.
Elice F, Fink L, Tricot G, Barlogie B, Zangari M (2006) Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134(4):399–405PubMed
35.
Leebeek FW (2016) Update of thrombosis in multiple myeloma. Thromb Res 140(Suppl 1):S76–S80PubMed
36.
Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M et al (2013) Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 88(9):765–770PubMed
37.
van Marion AM, Auwerda JJ, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG et al (2005) Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 94(12):1341–1343PubMed
38.
Ghosh N, Ye X, Ferguson A, Huff CA, Borrello I (2011) Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol 152(5):593–599PubMedPubMedCentral
39.
Rosse W (2000) Paroxysmal nocturnal hemoglobinuria. In: Hematology: basic principles and practice, 3rd edn. Churchill Livingstone, New York, p 331–342
40.
Risitano AM (2012) Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217(11):1080–1087PubMed
41.
Risitano AM (2013) Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Complement therapeutics. Adv Exp Med Biol 735:155–172PubMed
42.
Lewis DA, Nyska A, Potti A, Hoke HA, Klemp KF, Ward SM et al (2006) Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis. Thromb Res 118(6):747–753PubMed
43.
Studt J-D, Hovinga JAK, Antoine G, Hermann M, Rieger M, Scheiflinger F et al (2005) Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105(2):542–544PubMed
44.
Haybar H, Khodadi E, Kavianpour M, Saki N (2018) Mutations and common polymorphisms in ADAMTS13 and vWF genes responsible for increasing risk of thrombosis. Cardiovasc Haematol Disord Drug Targets (Formerly Curr Drug Targets Cardiovasc Hematol Disord) 18(3):176–181
45.
Catani MV, Bernassola F, Rossi A, Melino G (1998) Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Commun 249(1):275–278PubMed
46.
Shao J, Miyata T, Yamada K, Hanafusa N, Wada T, Gordon KL et al (2001) Protective role of nitric oxide in a model of thrombotic microangiopathy in rats. J Am Soc Nephrol 12(10):2088–2097PubMed
47.
Ploug M, Plesner T, Ronne E, Ellis V, Hoyer-Hansen G, Hansen NE et al (1992) The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 79(6):1447–1455PubMed
48.
Sloand EM, Pfannes L, Scheinberg P, More K, Wu CO, Horne M et al (2008) Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol 36(12):1616–1624PubMedPubMedCentral
49.
Maroney S, Cunningham A, Ferrel J, Hu R, Haberichter S, Mansbach C et al (2006) A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 4(5):1114–1124PubMed
50.
Maroney SA, Mast AE (2008) Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci 38(1):9–14PubMedPubMedCentral
51.
52.
Colaizzo D, Tiscia GL, Bafunno V, Amitrano L, Vergura P, Lupone MR et al (2011) Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res 128(3):233–236PubMed
53.
Akpan IJ, Stein BL (2018) Splanchnic vein thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 13(3):183–190PubMed
54.
Smalberg JH, Arends LR, Valla DC, Kiladjian J-J, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120(25):4921–4928PubMed
55.
Bagheropur S, Ehsanpour A, Birgani MT, Saki N (2018) JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms. Mag Eur Med Oncol 11(2):152–157
56.
Villani L, Bergamaschi G, Primignani M, Rosti V, Carolei A, Poletto V et al (2012) JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms. Leuk Res 36(1):e7–e9PubMed
57.
Spaander M, Hoekstra J, Hansen B, Van Buuren H, Leebeek F, Janssen H (2013) Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost 11(3):452–459PubMed
58.
Shahrabi S, Behzad MM, Jaseb K, Saki N (2018) Thrombocytopenia in leukemia: pathogenesis and prognosis. Histol Histopathol 33(9):895–908PubMed
59.
60.
Kwaan HC, Cull EH (2014) The coagulopathy in acute promyelocytic leukaemia—what have we learned in the past twenty years. Best Pract Res Clin Haematol 27(1):11–18PubMed
61.
Koch A, Meesters MI, Scheller B, Boer C, Zacharowski K (2013) Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care 17(5):R198PubMedPubMedCentral
62.
63.
LeBlanc R, Roy J, Demers C, Vu L, Cantin G (1999) A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant 23(10):991PubMed
64.
Topcuoglu P, Arat M, Dalva K, Özcan M (2004) Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 33(2):171PubMed
65.
De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L et al (2005) The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 3(9):1985–1992PubMed
66.
67.
Amin Asnafi A, Jalali MT, Pezeshki SMS, Jaseb K, Saki N (2019) The association between human leukocyte antigens and ITP, TTP, and HIT. J Pediatr Hematol Oncol 41(2):81–86PubMed
68.
Chung W-S, Lin C-L, Kao C-H (2015) Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism. Thromb Haemost 114(10):812–818PubMed
69.
Chung WS, Lin CL, Chang SN, Lu CC, Kao CH (2014) Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost 12(4):452–458PubMed
70.
71.
Chung W-S, Peng C-L, Lin C-L, Chang Y-J, Chen Y-F, Chiang JY et al (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73(10):1774–1780PubMed
72.
Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131(4):417–430PubMed
73.
Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS (1993) Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Investig 91(4):1721–1730PubMedPubMedCentral
74.
Khanna HK, Stevens AC (2017) Diabetic myonecrosis: a rare complication of diabetes mellitus mimicking deep vein thrombosis. Am J Case Rep 18:38PubMedPubMedCentral
75.
Stein PD, Goldman J, Matta F, Yaekoub AY (2009) Diabetes mellitus and risk of venous thromboembolism. Am J Med Sci 337(4):259–264PubMed
76.
Grant P (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262(2):157–172PubMed
77.
Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ (2010) Platelet abnormalities in diabetes mellitus. Diabetes Vasc Dis Res 7(4):251–259
78.
Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP (2011) Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34(Supplement 2):S285–S290PubMedPubMedCentral
79.
Stavenuiter F, Bouwens EA, Mosnier LO (2013) Down-regulation of the clotting cascade by the protein C pathway. Hematol Educ/Congr Eur Hematol Assoc Eur Hematol Assoc Congr Educ Program NIH Public Access 7:365–374
80.
81.
Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I (1998) Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the prevention of the risk of obesity. Diabetes Care 21(11):1967–1972PubMed
82.
Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ (2002) The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51(1):189–197PubMed
83.
Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22(3):215–224PubMed
84.
Lu D-Y, Huang C-C, Huang P-H, Chung C-M, Lin S-J, Chen J-W et al (2014) Metformin use in patients with type 2 diabetes mellitus is associated with reduced risk of deep vein thrombosis: a non-randomized, pair-matched cohort study. BMC Cardiovasc Disord 14(1):187PubMedPubMedCentral
85.
Zhao Z, Wang S, Ma W, Kong G, Zhang S, Tang Y et al (2014) Diabetes mellitus increases the incidence of deep vein thrombosis after total knee arthroplasty. Arch Orthop Trauma Surg 134(1):79–83PubMed
86.
Gandhi R, Razak F, Tso P, Davey JR, Mahomed NN (2009) Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty. J Rheumatol 36(10):2298–2301PubMed
87.
Bhasin R, Ghobrial I (2013) Diabetic myonecrosis: a diagnostic challenge in patients with long-standing diabetes. J Community Hosp Intern Med Perspect 3(1):20494
88.
89.
Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G et al (2001) Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 44(10):2255–2262PubMed
90.
Holmqvist ME, Neovius M, Eriksson J, Mantel Ä, Wållberg-Jonsson S, Jacobsson LT et al (2012) Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA 308(13):1350–1356PubMed
91.
Mukubo Y, Kawamata M (2004) Perioperative hypercoagulability in patients with rheumatoid arthritis: sonoclot study. J Anesth 18(1):62–64PubMed
92.
93.
Lee D-K, Kim H-J, Lee D-H (2016) Incidence of deep vein thrombosis and venous thromboembolism following TKA in rheumatoid arthritis versus osteoarthritis: a meta-analysis. PLoS ONE 11(12):e0166844PubMedPubMedCentral
94.
95.
Xu J, Lupu F, Esmon CT (2010) Inflammation, innate immunity and blood coagulation. Hämostaseologie 30(01):5–9PubMed
96.
Brill A, Fuchs T, Savchenko A, Thomas G, Martinod K, De Meyer S et al (2012) Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10(1):136–144PubMedPubMedCentral
97.
Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J et al (2002) Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children. Thromb Haemost 87(04):593–598PubMed
98.
Maufus M, Elias A, Barrellier M-T, Pernod G (2018) Diagnosis of deep vein thrombosis recurrence: ultrasound criteria. Thromb Res 161:78–83PubMed
99.
Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J et al (2003) Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 349(13):1227–1235PubMed
100.
Wang X, Sundquist K, Elf JL, Strandberg K, Svensson PJ, Hedelius A et al (2016) Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. Thromb Haemost 116(08):328–336PubMed
101.
Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R et al (2016) Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 41(1):32–67PubMedPubMedCentral
102.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M et al (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219PubMed
103.
de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M et al (2008) Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112(8):3099–3106PubMed
104.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355(12):1233–1243PubMed
105.
Griffin M, Munir T (2017) Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide. Ther Adv Hematol 8(3):119–126PubMed
106.
De Stefano V, Finazzi G, Barbui T (2018) Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer J 8(7):65PubMedPubMedCentral
107.
Napolitano M, Valore L, Malato A, Saccullo G, Vetro C, Mitra ME et al (2016) Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leuk Lymphoma 57(1):116–119PubMed
108.
Emmi G, Silvestri E, Squatrito D, Amedei A, Niccolai E, D’Elios MM et al (2015) Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J 13(1):15PubMedPubMedCentral
109.
110.
Al-Ani B (2013) Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide. Saudi Med J 34(5):477–483PubMed
111.
Kaiser R, Cleveland CM, Criswell LA (2009) Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 68(2):238–241PubMed
Metadaten
Titel
Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders
verfasst von
Hassan Alipanahzadeh
Reza Ghulamreza
Mohammad Shokouhian
Marziye Bagheri
Mohsen Maleknia
Publikationsdatum
05.12.2019
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 2/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-02005-6

Weitere Artikel der Ausgabe 2/2020

Journal of Thrombosis and Thrombolysis 2/2020 Zur Ausgabe

BriefCommunication

Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel

ReviewPaper

The efficacy and safety of tranexamic acid in the treatment of intertrochanteric fracture: an updated meta-analysis of 11 randomized controlled trials

OriginalPaper

Soluble platelet endothelial cell adhesion molecule 1 (sPECAM-1) improves diagnostic accuracy of D-Dimer in patients with suspected deep vein thrombosis (DVT)

ReviewPaper

Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis

OriginalPaper

Heparin resistance in COVID-19 patients in the intensive care unit

OriginalPaper

Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise